A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

“It’s easier to transmit HIV in these settings. If people are pregnant ... but because the first PrEP drug, Truvada by Gilead Sciences, was costly, it was used primarily by white, gay men in major U.S ...

March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline ...

He was living with hepatitis B (HBV) and with advanced HIV. "Since both viruses are bloodborne and transmitted in similar ways, coinfections can be quite common," says Dr. Anchalee Avihingsanon ...

HIV-HBV coinfection rates can reach 25% in ... Originally published by Gilead Sciences. View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.